FIRST ALEXIS CARREL SYMPOSIUM

LIPID MEDIATORS IN ORGAN TRANSPLANTATION

TENTATIVE PROGRAM

April 8 - 10, 1986

GORMAN AUDITORIUM.

Georgetown University Medical Center

Washington D.C.

1/14/86

Source: https://www.industrydocuments.ucsf.edu/docs/rmjv0000

TUESDAY EVENING

Life of Dr. Carrel

Rev. J. T. Durkin, Georgetown University, Washington D.C.*

Medical Achievements of Dr. Carrel

Dr. T. I. Malinin, Univ. Miami, Florida.*

RECEPTION

Source: https://www.industrydocuments.ucsf.edu/docs/rmjv0000

Wednesday - Thursday

*CONFIRMED PARTICIPATION

P.W. Ramwell, Georgetown Univ. Washington D.C.*

Pathophysiological Role of Eicosanoids.

J. Rokash, Merck-Frosst, Point Claire Duval, Canada.*

Lipoxins - Do they have a Biological Role.

M. Foegh, Georgetown University, Washington D.C.*

The Eicosanoids and their Relation to Interleukin 1, Interleukin 2 and Gamma-Interferon.

W. Farrar, NCI, Frederick, M.D.*

Prostaglandin Feedback Mechanism for Interleukin 2.

J.Humes, Merck, Rahway, N.J.*

HETE Regulation of Leukotrienes.

C.T. Van Buren & B.D. Kahan, Univ. Texas, Houston, TX

Cyclosporin A and its Effect on Interleukin 1, Interleukin 2 and Gamma-Interferon.

S.A. Rosenberg, NIH.

Patient Experience with Interleukin 2 and the Promotion of Killer Cell Activity.

M. Goldyne, UCFS, CA.*

Lymphocytes and Macrophage Interaction through Arachidonate Metabolites.

F. Hirata, NIH*

Which Efects of Corticosteroids are Expressed through Lipocortin.

Source: https://www.industrydocuments.ucsf.edu/docs/rmjv0000

M. Hess, Medical College of Virginia, Richmond, VA.*

Does Cyclosporine Accelerate Atherosclerosis?

S. Azaz & S.W. Jameison, Stanford, CA*

Possible Attenuation of Graft Atherosclerosis with PGE Analogues.

M. Rola-Pleszczynski, Univ. Sherbrooke, Sherbrooke, Canada.*

Cytotoxic Cells and their Modulation by Leukotrienes and Prostaglandins.

J.S. Goodwin, Albequerque, NM.*

Role of LTB_4 in T-Cell Activation.

A. Ford-Hutchinson, Merck-Frosst, Point Claire Duval, Canada*

Leukotrienes and Leukocyte Function.

B.S. Khirabadi, Georgetown Univ. Washington D.C.*

Experimental Prolongation of Graft Survival with 5-Lipoxygenase Inhibitors.

P. Klotman, Duke Univ., Durham, NC.*

Lipid Mediators in Renal Allograft Rejection..

C.B. Anderson & J.M. Mangino, Washington Univ. St. Louis. MO.*

Eicosanoids in Renal Allograft Rejection.

P. Hayry, Univ. Helsinki, Helsinki, Finland.*

Antigen Expression in Graft Rejection.

T.B. Strom, Harvard Med. School, Boston, MA*

Title to be determined.

Source: https://www.industrydocuments.ucsf.edu/docs/rmjv0000

C.B. Carpenter, Harvard Med. School, Boston, MA.

Prostaglandin E and Allograft Survival.

H. Sinzinger, Univ. Vienna, Vienna, Austria.

Prostacyclin and Improved Graft Survival.

D. Sachs, NIH.

Miniature Swine as a Model for Organ Transplantation.

P. Braquet, Henri Beaufour Institut, Paris, France.*

Biological Role of Platelet-Activating Factor (PAF).

G. Camussi, Buffolo N.Y./Univ. Torino, Torino, Italy.*

PAF and Transplant Rejection.

D. Hartmann, Georgetown Univ., Washington D.C.*

Lymphocyte Proliferation and PAF.

Source: https://www.industrydocuments.ucsf.edu/docs/rmjv0000